HomeAI · summaries
Storia in 2 fonti
Biocon stock ticks up as Yesafili Biosimilar clinical data gets published in peer-reviewed journals
Biocon's stock rises 1.22% as clinical data for Yesafili biosimilar is published, marking a key milestone for the company.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Biocon stock ticks up as Yesafili Biosimilar clinical data gets published in peer-reviewed journals
Biocon's stock rises 1.22% as clinical data for Yesafili biosimilar is published, marking a key milestone for the company.
- ·
morningstar.com
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)